Spero Therapeutics, Inc. revenue for the last year amounted to 103.78 M USD, the most of which — 103.78 M USD — came from its highest performing source at the moment, Novel Treatments for Multi-drug Resistant Bacterial Infections, the year earlier bringing 53.51 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Spero Therapeutics, Inc. 103.78 M USD, and the year before that — 53.51 M USD.